BAYN.DE - Bayer Aktiengesellschaft

XETRA - XETRA Delayed Price. Currency in EUR
92.05
-0.30 (-0.32%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close92.35
Open92.10
Bid0.00 x 28400
Ask0.00 x 2100
Day's Range91.48 - 93.35
52 Week Range87.40 - 118.04
Volume4,626,312
Avg. Volume3,075,485
Market Cap86.432B
Beta0.90
PE Ratio (TTM)11.14
EPS (TTM)8.26
Earnings DateSep 5, 2018
Forward Dividend & Yield2.76 (2.93%)
Ex-Dividend Date2018-05-28
1y Target Est120.99
  • Bayer to stop sales of birth control device tied to injuries
    Associated Press4 hours ago

    Bayer to stop sales of birth control device tied to injuries

    WASHINGTON (AP) — The maker of a permanent contraceptive implant subject to thousands of injury reports and repeated safety restrictions by regulators said Friday that it will stop selling the device in the U.S., the only country where it remains available.

  • Reuters8 hours ago

    Bayer to phase out Essure birth control device in U.S.

    Life sciences company Bayer AG (BAYGn.DE) said on Friday it would discontinue the sale of its birth control product Essure in the United States, citing a decline in sales of the implantable device that made the business no longer sustainable. The decision followed an announcement by the company in September 2017 that it would discontinue the sale of the contentious sterilization device in all countries outside the United States. Bayer said in a statement that the decision was not related to safety concerns.

  • Reuters8 hours ago

    Bayer to phase out Essure birth control device in U.S.

    Life sciences company Bayer AG said on Friday it would discontinue the sale of its birth control product Essure in the United States, citing a decline in sales of the implantable device that made the business no longer sustainable. The decision followed an announcement by the company in September 2017 that it would discontinue the sale of the contentious sterilization device in all countries outside the United States. Bayer said in a statement that the decision was not related to safety concerns.

  • Bayer to Stop Selling Contraceptive Implant Essure After Threats by FDA
    Bloomberg10 hours ago

    Bayer to Stop Selling Contraceptive Implant Essure After Threats by FDA

    Bayer AG said it is pulling a female contraceptive implant off the U.S. market after the Food and Drug Administration threatened the company with civil and criminal penalties if it didn’t tell patients about the product’s serious health risks. Bayer said in a statement Friday that it will stop selling the Essure device in the U.S. after Dec. 31 because a decline in sales made the business unsustainable. Essure is a permanent contraceptive developed as an alternative to surgical techniques such as tying or severing the fallopian tubes.

  • Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug
    Bloomberg7 days ago

    Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug

    Bayer AG and Johnson & Johnson won a judge’s ruling that upheld the validity of a patent on the blood-thinning drug Xarelto and will keep Mylan NV from selling a generic, low-cost version until August 2024, when the patent expires. Mylan NV and Sigmapharm Laboratories LLC failed to prove the patent shouldn’t have been issued, U.S. District Court Judge Lawrence Stengel in Wilmington, Delaware, said. The companies can’t sell their generic versions of the drug until the patent expires, the judge said in a separate order.

  • U.S. judge allows lawsuits over Monsanto's Roundup to proceed to trial
    Reuters10 days ago

    U.S. judge allows lawsuits over Monsanto's Roundup to proceed to trial

    The decision by U.S. District Judge Vince Chhabria in San Francisco followed years of litigation and weeks of hearings about the controversial science surrounding the safety of the chemical glyphosate, the key ingredient in Monsanto's top-selling weed-killer. Monsanto is now a unit of Bayer AG (BAYGn.DE), following a $62.5 billion takeover of the U.S. seed major which closed in June. The U.S. Environmental Protection Agency last September concluded glyphosate is likely not carcinogenic to humans.

  • Reuters10 days ago

    U.S. judge allows lawsuits over Monsanto's Roundup to proceed to trial

    The decision by U.S. District Judge Vince Chhabria in San Francisco, California, followed years of litigation and weeks of hearings about the controversial science surrounding the safety of the chemical glyphosate, the key ingredient in Monsanto's top-selling weed-killer. Monsanto is a unit of Bayer AG (BAYGn.DE), following the $62.5 billion takeover of the U.S. seed major which wrapped up in June.

  • Monsanto Judge Won't Block Cancer Victims' Key Witnesses
    Bloomberg10 days ago

    Monsanto Judge Won't Block Cancer Victims' Key Witnesses

    Monsanto Co. lost a court ruling that permits key witnesses to testify in a lawsuit claiming the company’s Roundup weed killer caused cancer for farmers and other users. It’s a significant victory for the cancer victims, who need expert testimony to advance more than 300 suits in San Francisco federal court seeking to hold Monsanto liable for failing to warn consumers about the risk of using the weed killer. A jury trial hasn’t been scheduled, but the decision puts pressure on Monsanto to settle the cases.

  • Monsanto may appeal Brazil royalties ruling
    Reuters10 days ago

    Monsanto may appeal Brazil royalties ruling

    Monsanto Co is considering appealing a Brazilian court ruling obliging it to deposit in an escrow account the royalties related to its Intacta RR2 Pro soy seed biotechnology, the company said in a statement on Tuesday. "Monsanto is weighing options for appealing (the ruling) and will take all measures to protect its legal rights," the statement said. Last week, a Brazilian judge ordered units of Monsanto Co to deposit the royalties related to that genetically modified seed in an escrow account pending the outcome of litigation over a patent dispute between Brazilian soy growers and the U.S. seeds company, now a unit of Bayer AG.

  • Reuters10 days ago

    Monsanto may appeal Brazil royalties ruling

    Monsanto Co is considering appealing a Brazilian court ruling obliging it to deposit in an escrow account the royalties related to its Intacta RR2 Pro soy seed biotechnology, the company said in a statement on Tuesday. "Monsanto is weighing options for appealing (the ruling) and will take all measures to protect its legal rights," the statement said. Last week, a Brazilian judge ordered units of Monsanto Co to deposit the royalties related to that genetically modified seed in an escrow account pending the outcome of litigation over a patent dispute between Brazilian soy growers and the U.S. seeds company, now a unit of Bayer AG.

  • Reuters16 days ago

    Brazil judge orders Monsanto to deposit royalties related to GMO seed

    A Brazilian judge has ordered local units of Monsanto Co to deposit royalties related to a GMO soy seed technology in an escrow account, in a decision likely to hinder the U.S. seed company's ability to collect royalties from the business. The ruling on Tuesday relates to a patent dispute between Brazilian soy growers in the state of Mato Grosso and Monsanto, which was recently acquired by Germany's Bayer AG in a 63 billion-euro deal. The judge ordered local units of Monsanto to deposit in an escrow account royalties related to the Intacta RR2 Pro genetically modified soy seed technology pending the end of the patent litigation, according to the decision, which was seen by Reuters.

  • Reuters16 days ago

    Brazil judge orders Monsanto to deposit royalties related to GMO seed

    A Brazilian judge has ordered local units of Monsanto Co to put royalties related to a GMO soy seed technology in an escrow account, in a decision likely to hinder the U.S. seed company's ability to collect royalties from the business. The July 3 ruling relates to a patent dispute between Brazilian soy growers in the state of Mato Grosso and Monsanto, which was recently acquired by Germany's Bayer AG in a 63 billion-euro deal. The judge ordered local units of Monsanto to deposit in an escrow account royalties related to the Intacta RR2 Pro genetically modified soy seed technology pending the end of the patent litigation, according to the decision seen by Reuters.

  • Covestro CEO Sweeps Away Bayer Culture With Workforce Overhaul
    Bloomberg17 days ago

    Covestro CEO Sweeps Away Bayer Culture With Workforce Overhaul

    German chemicalmaker Covestro AG took a financial leap forward after separating from Bayer AG three years ago. Chief Executive Officer Markus Steilemann says it’s now time to make a cultural split.

  • Reuters17 days ago

    Bayer sees Brazil as key growth driver for global crop division

    Bayer AG's crop science unit will lead revenue gains in Brazil this year and next as the South American country becomes the company's main driver of growth and its second biggest market, the global head of the crop science division said on Tuesday. Unit head Liam Condon, speaking to a gathering of journalists in São Paulo, said that after Bayer completes its integration of Monsanto Co following the recent closing of the acquisition, the combined entity will have revenue of about 15 billion reais ($3.9 billion) in Brazil.

  • Reuters17 days ago

    Bayer sees Brazil as key growth driver for global crop division

    SAO PAULO (Reuters) - Brazil is the second most important market for Germany's Bayer AG (BAYGn.DE) and will be a growth driver for its crop science division, global crop science chief executive officer ...

  • Does Monsanto Company’s (NYSE:MON) Debt Level Pose A Problem?
    Simply Wall St.25 days ago

    Does Monsanto Company’s (NYSE:MON) Debt Level Pose A Problem?

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Monsanto Company (NYSE:MON) a safer option. Risk-averse investors who are attracted to diversified streams ofRead More...

  • The Wall Street Journal28 days ago

    [$$] Life After the Monsanto Sale

    After nearly 40 years at Monsanto Co., the company that spread genetically engineered seed across the U.S. heartland and beyond, now-former chief executive Hugh Grant doesn’t know exactly what’s next, aside from a desire to stay in agriculture. Mr. Grant earlier this month oversaw the sale of his former employer to Bayer AG, a more-than-$60 billion deal that has reordered the global agricultural industry. The German drug and chemical conglomerate now is the world’s biggest supplier of crop seeds and pesticides to farmers, acquiring the top global franchise in biotech seeds engineered to survive chemical sprays and repel destructive bugs—products pioneered by Monsanto that have transformed American agriculture.

  • Moody's28 days ago

    Monsanto Finance Canada Co. -- Moody's downgrades Monsanto's ratings to Baa1; outlook negative

    Moody's Investors Service, ("Moody's") downgraded Monsanto Company's (Monsanto's) and Monsanto Finance Canada Co.'s long-term debt ratings to Baa1 from A3 due to its acquisition by Bayer AG (Baa1 negative) on June 7, 2018. Moody's also withdrew Monsanto's Prime-2 commercial paper rating.

  • Is Bayer Aktiengesellschaft’s (FRA:BAYN) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.29 days ago

    Is Bayer Aktiengesellschaft’s (FRA:BAYN) Balance Sheet Strong Enough To Weather A Storm?

    Investors pursuing a solid, dependable stock investment can often be led to Bayer Aktiengesellschaft (FRA:BAYN), a large-cap worth €85.95b. Risk-averse investors who are attracted to diversified streams of revenue andRead More...

  • Bayer's Bond Sale Targets Monsanto Acquisition Funds
    Bloomberglast month

    Bayer's Bond Sale Targets Monsanto Acquisition Funds

    Bayer AG launched Europe's second-largest corporate bond sale this year, putting the company on track to complete a two-day, $21 billion fundraising drive to pay for the Monsanto Co. acquisition. Bloomberg's ...

  • $21 Billion Shows Two Bond Markets Aren't Equal
    Bloomberglast month

    $21 Billion Shows Two Bond Markets Aren't Equal

    Bayer AG is finding it harder to sell debt in its home country than in the U.S., a telling sign of the respective health of the euro and dollar credit markets. The German chemical giant wanted to complete the financing for its $63 billion acquisition of Monsanto Co. — but it had to pay up to do that in Europe. Once the new issue premium — the extra yield investors are offered to buy the new securities over existing ones of a comparable maturity — was reduced by the underwriters, the bonds were eventually priced close to where Bayer's existing bonds are trading.

  • Bayer’s Bond Puts the Fed in Its Place
    Bloomberglast month

    Bayer’s Bond Puts the Fed in Its Place

    German chemical giant Bayer AG has finally launched one of the biggest corporate bond sales of the year. This is an important test of the health of the market, given the Federal Reserve’s move last week to raise rates and stoke expectations for additional tightening.

  • Monsanto Faces Man Dying of Cancer in Roundup Trial
    Bloomberglast month

    Monsanto Faces Man Dying of Cancer in Roundup Trial

    Lee Johnson’s doctors didn’t think he’d live long enough to testify in court that exposure to Monsanto Co.’s Roundup weed killer caused his deadly cancer. As groundskeeper for the school district in Benicia, California, about 40 miles east of San Francisco, Johnson mixed and sprayed hundreds of gallons of Roundup. Glyphosate, the main ingredient in Roundup, was first approved for use in Monsanto’s weed killer in 1974.

  • Bayer's Bond Sale Targets Monsanto Acquisition Funds
    Bloomberg Videolast month

    Bayer's Bond Sale Targets Monsanto Acquisition Funds

    Jun.19 -- Bayer AG launched Europe's second-largest corporate bond sale this year, putting the company on track to complete a two-day, $21 billion fundraising drive to pay for the Monsanto Co. acquisition. Bloomberg's Molly Smith reports on "Bloomberg Daybreak: Americas."